Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Molecular Health and Gen Era Diagnostics agree to collaborate in the field of precision oncology in Turkey

Heidelberg, 19. October 2021 – Molecular Health and the life science company Gen Era Diagnostics have signed a collaboration agreement to optimize the personalized treatment of patients with cancer. For this purpose, Gen Era will provide the MH Guide software platform to twenty laboratories in Turkey to use in the interpretation of tumor data.

“We are pleased to have Molecular Health on board in the near future as an experienced partner in precision medicine. With MH Guide, we can analyze and interpret molecular genetic data even faster and more comprehensively. This is an important addition to our service and product portfolio,” explains Damla Bozkulak, Head of Marketing and Business Development at Gen Era Diagnostics.

Gen Era Diagnostics is one of the leading product and service providers in the field of molecular diagnostics in Turkey. Founded in 2013, the company supports scientists, clinicians, and laboratories in the investigation of diseases and the treatment of patients. Gen Era’s offering includes solutions and services for molecular diagnostics in the fields of oncology, cardiology, and metabolic diseases, among others. In addition, the company offers services for the life sciences, including genomics, proteomics, and cell analyses.

“With MH Guide, doctors can manage the flood of data from molecular genetic testing and translate it into targeted therapy recommendations. We value the trust that Gen Era Diagnostics has placed in our technology and are convinced that patients in Turkey will benefit from it,” explains Thomas Holtrup, Senior Vice President, Head of Sales & Business Development, EMEA, at Molecular Health.

MH Guide is an analysis software for interpreting molecular data from cancer patients. It summarizes in a report the relevant genetic changes of a tumor that can be specifically addressed in individual patients either therapeutically or in clinical trials. In this way, treatment options can be expanded, especially for patients with metastatic disease.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About Gen Era Diagnostics:

Gen Era Diagnostics is a biotech company founded in 2013. It is one of the leading institutions in the fields of molecular diagnostics and life science research in Turkey. With its service and product portfolio, Gen Era Diagnostics supports scientists, clinics and laboratories in the research, diagnosis and treatment of diseases. This includes oncological indications, cardiology, hematology and rare genetic diseases. In addition, Gen Era supports research projects in the fields of genomics, proteomics and cell analysis and offers bioinformatics services for scientific institutions.

More information at  Gen Era Diagnostik

Download pdf

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update

Heidelberg, September 30, 2021. Molecular Health has launched the latest version of its analysis software MH Guide. This software, which is used by pathology laboratories and molecular tumor boards, now has improved search capabilities to identify patient- relevant clinical studies. With the VCF Adapter Suite, Molecular Health also offers a conversion tool to easily integrate data from the most common NGS sequencing systems.

The current version of MH Guide contains an optimized search and filter function for identifying relevant clinical studies. This allows more cancer patients to access studies that are suitable for them.

The VCF Adapter Suite was introduced alongside MH Guide 5.0. This conversion tool enables a simple connection to common NGS analysis systems. Currently, the following data can be converted into an MH Guide-compatible format:

• Illumina (TSO500, TST170, AmpliSeq)
• ArcherDX
• Qiagen
• Thermo Fisher Oncomine
• AmoyDx

This facilitates individual conversions and supports integration into fully automated processes.

“Many molecular pathology laboratories are now using our software for patients, who can benefit from targeted therapy or participation in a clinical trial based on the comprehensive analysis of their tumor genome,” explains PD Dr. Christian Meisel, Chief Medical Officer of Molecular Health. “This means that the treatment spectrum can be expanded and affected people can be given options,” Meisel continues.

“We are continuously working on improvements to our software and will continue to accommodate the use requirements of molecular tumor boards in further updates of MH Guide. Our goal is to provide the best possible information for evidence-based therapy decisions at all times,” explains Dr. Matthias Kopf, Head of Product Management at Molecular Health.

MH Guide is a browser-based software that is used in therapy planning for cancer patients. The software enables the automatic analysis of molecular data obtained using Next Generation Sequencing (NGS), and provides treating physicians with an evidence-based report for personalized therapy approaches. This report contains information on potentially effective targeted and immuno-oncological therapies and on ongoing clinical studies for which the patient is eligible. With the current software update (MH Guide 5.0), Molecular Health has made an improved version of the application available since September 1, 2021.

MH Guide is a proprietary technology from Molecular Health, an internationally active biotech IT company in Heidelberg, Germany. The software compares sequence data from molecular testing with information from one of the world’s largest and growing knowledge platforms (Dataome). Thus, the tool enables molecular pathologists and practitioners to keep pace with rapidly expanding medical knowledge and use insights for the treatment of their patients. 

Users can access the current version of MH Guide via https://analysis.mh.guide. Interested parties can obtain further information on the customerservice@molecularhealth.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

Download pdf

What’s new in MH Guide version 5.0

Discover what’s new in MH Guide version 5.0

As of September 1, 2021, version 5.0 of MH Guide is available. The improved solution offers numerous updates and new features, including:

  • Flexible customizations of the MH Guide report, including custom input fields
  • Optimized search and filter tools to better identify relevant clinical trials and
    highlight these in MH Guide reports
  • The MH VCF Adapter Suite to easy convert variant data into an MH-compatible VCF format

Learn in detail how MH Guide 5.0 accelerates insights.
Please download PDF here.

Molecular Health and Korean EONE-Diagnomics Genome Center (EDGC) join forces in liquid biopsy-based precision medicine

Heidelberg/Incheon, 15. September 2021. Molecular Health GmbH will collaborate with EONE-Diagnomics Genome Center Co. Ltd. (EDGC) to help its healthcare provider customers identify personalized treatment options for cancer patients. The collaboration is intended to establish leadership in the fast-growing precision medicine market for liquid biopsy. Therefore, the two partners combine two major proprietary technologies, Molecular Health’s MH Guide and EDGC’s ONCOCATCH-CDxTM. This allows comprehensive genomic tumor profiling to guide treatment in solid tumors.

“The cooperation between Molecular Health and EDGC connects two well-established players in the field of precision medicine and forms an alliance that has the potential to significantly improve diagnosis and tailored treatment of cancer patients”, says Stephan Hettich, SVP, Head of Sales & Business Development, APAC with Molecular Health. “We are very happy to have found a strong and experienced partner like EDGC to capture the Asian market together.”

EDGC is an international joint venture based in South Korea that develops leading-edge technology for genome analysis and precision as well as personalized medicine. With ONCOCATCH-CDx the research and development company developed a unique non-invasive biopsy for early diagnosis, companion diagnostics and monitoring of all-stage cancer. The test analyses circulating tumor DNA (ctDNA), which is released from cancer cells into the bloodstream, through next-generation sequencing technology and state-of-the-art in-house bioinformatics. This provides the basis for personalized medicine prescription and helps doctors and patients in the decision-making. The global life science journal GenomeWeb labeled ONCOCATCH as ‘one of the world’s best-advanced technologies for early cancer diagnosis.

As part of the cooperation, EDGC aims to utilize Molecular Health’s MH Guide, analysis software that supports oncologists and molecular pathologists in the interpretation of large molecular datasets. Independent of the sequencing technology used, MH Guide can make complex datasets readable, and automatically identify genetic variants that are relevant for the treatment of cancer patients.

“When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx, qualitative comprehensive genomic profiling results can be provided to guide treatment in solid tumors,” Jeong Yoo-seok, EDGC Global Business Department Team Leader, summarizes the collaboration. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.

Please note
On 13th October 2021, EGDC and Molecular Health will be hosting a joint a webinar to give further details on the collaboration and the future joint activities. Partners may register by contacting yubinakim@edgc.com.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

Kim Seung-Gyun
EONE-Diagnomics Genome Center
seongyun.kim@edgc.com
Tel.: +82 32713-2190

About Molecular Health:

Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Read more on www.molecularhealth.com

About EONE-Diagnomics Genome Center:

EDGC is the international joint venture established in 2013 between EONE Laboratories and Diagnomics. EDGC has developed leading-edge technology for genome analysis through constant research and development and has established a business network to expand its influence on the global market. Because of that, EDGC diagnoses various diseases over the entire life cycle and provides clinical solution for precision and personalized medicine. As the global leader of genome business, EDGC has worked on global projects with the most influential BT and IT companies in the world such as Illumina and Microsoft.

Read more on www.edgc.com

Download pdf

Molecular Health and Universitätsmedizin Essen [Essen University Hospital] launch collaborative project to improve care for COVID-19 patients

Essen/Heidelberg, August 9, 2021. On August 1, 2021, the IT biotech company Molecular Health (MH) and Universitätsklinikum Essen kicked off a collaborative project funded by the BMG (Bundesministerium für Gesundheit [German Federal Ministry of Health]) to provide holistic and evidence-based care for COVID-19 patients. Using the MH Corona Explorer, a deeper understanding of the disease will be generated, linking the molecular basis to the clinical course of the disease. The goal is to enable innovative approaches to the diagnosis and treatment of COVID-19 patients and thus improve patient care.

The COVID-19 pandemic has crippled the world since 2020, with more than 190 million infections and more than 4 million deaths now reported. However, the state of knowledge about the disease is still insufficient, especially in terms of understanding COVID-19 disease at the molecular level in relation to a wide variety of clinical manifestations and symptoms. However, this understanding is critical to optimize diagnosis and treatment.

“To close this gap, we at Molecular Health have developed an enhanced COVID-19 disease model (“MH Corona Explorer”) based on our curated knowledge base (“DATAOME”) that links and represents the different symptoms of the disease with their molecular pathways. We are delighted to be able to implement this innovative collaborative project together with the experts and clinical expertise of Universitätsmedizin Essen,” said Dr. Anna Laib, Head of Medical Affairs and project leader of the Molecular Health collaboration at the kick-off meeting on August 3, 2021 at Uniklinikum Essen.

MH Corona Explorer’s in-silico approach as a browser-based application draws on biomedical knowledge published worldwide within the Molecular Health database. Using this digital model, the various clinical molecular features of COVID-19 are identified. This approach explains the long-term course of the disease, in addition to the variety of symptoms, while generating guidance for new treatment approaches.

To systematically advance the decoding of the disease, clinical data from up to 2,000 COVID-19 patients treated at the Universitätsmedizin Essen will be analyzed and linked to the digital model to identify new drug targets and biomarkers. Findings from the collaborative project, which is scheduled to run for approximately one year, may also provide defined predictors of progression to severe disease or even long-term disease due to COVID-19 (“long Covid”). “This is not just about funding research, but about funding the future of medicine – with this perspective, the joint project between the Universitätsmedizin Essen and Molecular Health offers an investment in the further development of healthcare,” commented Nick Schneider, Head of Division at the Bundesministerium für Gesundheit.

The relevance of the project is underlined by PD Dr. Adalbert Krawczyk, laboratory manager of infectiology and project manager on the part of the Universitätsmedizin Essen: “Not only do we have an extensive clinical dataset of COVID-19 patients, but we also have a large biospecimen set to control for potential biomarkers – we would like to capture these for early and reliable risk assessment of COVID-19 sufferers to use predictively or prognostically.”

Prof. Dr. med. Oliver Witzke, Director of the Klinik für Infektiologie [Clinic for Infectious Diseases] and the Westdeutsches Zentrum für Infektiologie [West German Center for Infectious Diseases] and project leader on the part of the Universitätsklinikums Essen, looks forward to the joint project with excitement: “Through this collaboration, our clinical knowledge from the field, along with Molecular Health’s in-depth COVID-19 disease model, can be made directly useful to physicians in patient care. In the future, we hope to be able to keep our finger on the pulse of the pandemic by networking information on new virus variants and correspondingly changing courses of disease: Emerging adaptable treatment strategies could serve as a key component of care, contributing to the management of this pandemic.” Initial results of the model project will be presented at a workshop this coming November.

Press contact:
Thomas König
Molecular Health
Thomas.Koenig@molecularhealth.com
Phone: +49 (0)6221-43512280

About Molecular Health:
Molecular Health is an international biotech IT company based in Heidelberg, Germany, that has been developing innovative software in the areas of in silico and precision medicine since 2004. Molecular Health’s solutions make it possible to transform large amounts of data into evidence-based, medically relevant decision support. They are used where precision medical patient care or efficient drug development requires increasingly complex data interpretations. At Molecular Health, specialists from the fields of medicine, data science, biology and bioinformatics, and software development are working to make Big Data useful for healthcare. The result is intuitive analysis applications that are individually tailored to different healthcare requirements. Molecular Health is a portfolio company of dievini Hopp Biotech holding GmbH & Co. KG.

Download pdf

Molecular Health and FALCO biosystems…

Heidelberg, Germany, March 02, 2021 – Molecular Health GmbH announced today that it has entered into an agreement with Kyoto-based FALCO biosystems Ltd. under which FALCO biosystems will use the products MH Guide/BRCA and MH Guide/Mendel to evaluate inherited genetic variants of BRCA1/2 and other heritable cancer-associated genes.

Inherited genetic variants can predispose an individual to cancer. Hereditary Breast and Ovarian Cancer (HBOC) Syndrome, for example, is caused by pathogenic mutations in distinct genes such as BRCA1/2, MLH1, MSH6, PMS2, respectively. Therefore, testing BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient’s individual risk of developing cancer1,2, and as a predictive biomarker and companion diagnostic test for certain drugs3. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole- exome or whole-genome data, so that many different hereditary diseases can be identified at once.

“With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention”, said Christian Meisel, MD, PhD, Chief Medical Officer at Molecular Health.

Under the terms of this collaboration, FALCO biosystems will perform the next-generation sequencing (NGS) process and variant identification using blood samples provided by the patient. Molecular Health will then analyze the variant data using MH Guide/BRCA or MH Guide/Mendel. To accurately distinguish benign from pathogenic variants, MH uses an in-house proprietary database called MH Dataome, which integrates the Japanese reference genome ToMMo 3.5KJPNv2 (MAF ≥ 1%) for improved variant filtering and classification. Molecular Health gratefully acknowledges the contribution of Tohoku Medical Megabank.

Download pdf